1580555-26-5

Uses

Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research[1][2].

in vivo

Taldefgrobep alfa (2 mg/kg; iv or sc; single dose) has rapid plasma clearance after intravenous administration in mice, but slow absorption (T_max=24 h) after subcutaneous administration with C_max=15.4 mg/mL and bioavailability (F)=84%^[1].

References

[1] Zhu Y, et al. LC-MS/MS multiplexed assay for the quantitation of a therapeutic protein BMS-986089 and the target protein Myostatin. Bioanalysis. 2016 Feb;8(3):193-204. DOI:10.4155/bio.15.238
[2] Straus M. 2023 Pipeline Report: Testing the Limits[J]. Pharmaceutical Executive, 2022, 42(12).

form	Liquid
color	Colorless to light yellow

Chemical Properties

Hazard Information

Uses

in vivo

References

Supplier